Abasaglar ® (insulin glargin)

För fullständig produktresumé för Abasaglar® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Abasaglar® (insulin glargin): Intravenös användning

Abasaglar administreras subkutant och ska inte administreras intravenöst.

Detailed Information

Abasaglar is administered subcutaneously and should not be administered intravenously because this could result in severe hypoglycemia.1

After injection of Abasaglar into the SC tissue, the acidic solution is neutralized, leading to formulation of micro-precipitates from which small amounts of Abasaglar are continuously released.1

Abasaglar has a slow and prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak.2

Special Warnings And Precautions For Use

Abasaglar is not the insulin of choice for the treatment of DKA. Instead, regular insulin administered intravenously is recommended in such cases.1

References

1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine injection) 100 units/mL

DKA = diabetic ketoacidosis

SC = subcutaneous

Datum fӧr senaste ӧversyn 2019 M04 02


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss